Overview: Recent advances in organic nitrates

Expert Opinion on Therapeutic Patents

Volumn 3, Issue 10, 1993, Pages 1499-1516

  Bertolini, Giorgio ^a   Sala, Alberto ^a  

^a Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (3 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 2 NITRATOPROPYL 3 NITRATOPROPYL ESTER; 5 DEOXY 5 (4 NICOTINOYL 1 PIPERAZINYL) 1,4:3,6 DIANHYDROIDITOL 2 NITRATE; 6 CHLORO 2 PYRIDYLMETHYL NITRATE; ACETYLCYSTEINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEDO 8956; CYCLIC GMP; CYCLOHEXANE DERIVATIVE; CYTOCHROME P450; ETHANOLAMINE DERIVATIVE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DERIVATIVE; ISOSORBIDE DINITRATE; LEMAKALIM; METYRAPONE; N CYANO N' (2 NITROXYETHYL) 3 PYRIDINECARBOXIMIDAMIDE; NITRIC OXIDE; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; THIAZOLIDINE DERIVATIVE; TIMONACIC; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANGINA PECTORIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STRIP; CAPACITANCE BLOOD VESSEL; CATTLE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; ENDOTHELIUM CELL; EXERCISE TEST; HEART INFARCTION; HEMODYNAMICS; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROBLAST; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRINZMETAL ANGINA PECTORIS; RABBIT; RAT; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; TACHYCARDIA; TRANSDERMAL DRUG ADMINISTRATION; UNSTABLE ANGINA PECTORIS; VASCULAR SMOOTH MUSCLE; VASODILATATION; VEIN;

EID: 0027425159     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.3.10.1499     Document Type: Article

References (89)

1. Organic nitrate ester: clini-cal use and mechanisms of actions
2. Nitrovasodilators as a new class of ocular hypotensive agents
3. S: The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa
4. Isosorbide dinitrate ameliorates myocardial ischaemia after de-velopment of collateral function in a ca-nine model
5. Bio-transformation of glyceryl trinitrate occurs concurrently with relaxation of rabbit aorta
6. GRUETTER CA: Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitro-prusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active in-termediates
7. Ni-tric oxide: physiology, pathophysiology and pharmacology
8. Mechanism of tolerance development to organic nitrates
9. Purification and characterization of glutathione-S-trans-ferases with an activity toward nitroglycerin from human aorta and heat
10. Nitric oxide for-mation during microsomal hepatic denitra-tion of glyceryl trinitrate: involvement of cy- -tochrome P450
11. Cytochrome P-450 mediates bioactivation of organic nitrates
12. Possible mechanisms of activa-tion of soluble guanylate cyclase by organic nitrates
13. An-tagonism of glycerol trinitrate activity by an inhibition of glutathione-S-transferase
14. Ni-troglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathione-S-transferase activity
15. Conver-sion of glyceryl trinitrate to nitric oxide in tolerant and non tolerant smooth muscle and endothelial cells
16. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production
17. Nitrate tolerance: a review of the evidence
18. Antianginal effects of nitro-glycerin patches
19. Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained ther-apy
20. Nitroglycerinin a transdermal therapeutic system in chronic heart failure
21. Haemodynamic and hormonal response to transdermal nitroglycerin in normal sub-jects and patients with congestive heart fail-ure
22. Reduced nitric oxide release causes ni-trates tolerance in the intact coronary cir-culation
23. Dissociation of cysteine and glutathione levels from nitro-glycerin-induced relaxation
24. Tolerance towards nitroglycerin induced in vivo is cor-related to a reduced cGMP response and an alteration in cGMP turnover
25. Nitroglycerin tolerance in vitro: effect on cGMP turnover in vascular smooth muscle
26. Total prevention of the development of in vitro tolerance to or-ganic nitrates
27. Desensitization to nitroglycerin in vascular smooth muscle from rat and hu-man
28. Nitro-glycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade
29. Induction of nitrate tolerance in human heart failure by continuous in-travenous infusion of nitroglycerin and re-versal of tolerance by N-acetyl cysteine, a sulfhydryl donor
30. Vivo induction and re-versal of nitroglycerin tolerance in human coronary arteries
31. Nitrate tolerance: the lack of effect of N-acetyl cysteine
32. Nitrate tolerance in epicardial arteries or in the venous system is not re-versed by N-acetyl cysteine in vivo, but tol-erance independent interaction exist
33. Nitric oxide liberating, soluble guanylate cyclase stimulating and vasorelaxing properties of the new nitrate compound SPM 3672
34. Nitrate action and tolerance in porcine vena cordis magna
35. Prophylactic therapy of angina pectoris with organic nitrates: re-lationship of drug efficacy and clinical ex-perimental design
36. Effects of long term administration of isosorbide dini-trate on the antianginal response to nitro-glycerin
37. Dis-position of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound in rats and dogs
38. Synthesis of stereoisomers of 1,4:3,6-dianhydrohexitol nitrate derivative, FR-14124
39. Car-diovascular effects of KW-3196, a novel va-sodilator, in dogs
40. Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4-nitroxycyclo-hexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys
41. Pharmaco-dynamics, pharmacokinetics and metabolism of isosorbide nitrate in awake dogs
42. Bio-transformation and pharmacokinetics of the nitrate trans-2-amino-2-methyl-N-(4-nitroxy cyclohexyl)-propionamide in dogs
43. Stimulation of hepatic glutathione formation by adminis-tration of L-2-oxothiazolidine-4-carboxilate, a 5-oxo-L-prolinase substrate
44. Central noradrenergic ac-tivity and the cardiovascular effects of ni-troglycerin and amyl nitrate
45. Clinical studies with transdermal nitroglycerin
46. DELBRO D: Pre- and post-ganglionic sympathetic nerve activity during induced hypotension with adenosine or soditun nitroprusside in the anesthetized rat
47. Electrocardio-graphic analysis of the effects of isosorbide-5-mononitrate on regional myocardial is-chaemia in conscious dogs
48. Cardiovascular profile of 5 novel notroesters: a comparative study with nitroglycerin in pigs with and without left ventricular dysfunction
49. Potassium channel modulators: scientific applications and therapeutic promise
50. Vasodilat-ing actions of 2-nicotinamide ethyl nitrate on porcine and guinea-pig coronary arteries
51. Cyclic GMP as possible medi-ator of coronary arterial relaxation by nico-randil (SG-75)
52. Pharmacological interaction exper-iments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil
53. Dual mechanism of the relaxing ef-fect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization
54. Vasodilating and hypotensive properties of KRN-2391
55. NISHIKORI K: Characteris-tics of ICRN-2391, a novel vasodilator, com-pared with those of cromakalim, pinacidil and nifedipine in rat aorta
56. Comparison of KRN-2391 with Nicorandil and Nifedipine on canine coronary blood flow: antagonism by glibenclamide
57. Tolerance to the increase in coronary blood flow induced by KRN-2391
58. Ism J: Effects of nipradilol, a new nitroester-containing beta-blocker, on forearm blood flow
59. Vasoactive and P-adrenore-ceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch. Int. Pharmaco-dyn
60. Nipradilol inhibits rat mesangial cell mitogenesis through the activation of soluble guanylate cyclase
61. Cyclic guanosine monophos-phate inhibition of contraction may be mediated through inhibition of phosphatidylinos-itolhydrolysis in rat aorta
62. Cyclic guano-sine monophosphate enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascu-lar smooth muscle
63. Pharmacological properties of 5-[(6,7,8-trimethoxy-4-quinazolinyflamino]-1-pentanyl nitrate maleate in cardiovascu-lar system
64. ITOH H: Selective in-hibitors of three forms of cyclic nucleotide phosphodiesterase
65. Synthesis and pharmacological evaluation of (nitrooxy)alkyl Apovincaminates
66. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives con-taining nitrooxyalkylester moieties at the 3-and 5- positions
67. Structure-activity study of antihypertensive 1,4-dihydropyridine deriva-tives having nitrooxyalkylester moieties at the 3- and 5- positions
68. The nitrovasodila-tors
69. 1,4:3,6-dianhydrohexitol nitrate derivatives
70. 1,4:3,6-dianhydro-hexitol nitrate derivatives